Deferasirox and vitamin D improves overall survival in elderly patients with acute myeloid leukemia after demethylating agents failure.

The prognosis of acute myeloid leukemia (AML) in elderly (≥65 years) patients is poor and treatment remains non-consensual especially for those who are not eligible for intensive therapies. Our group has shown that in vitro the iron chelator deferasirox (DFX) synergizes with vitamin D (VD) to promot...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Etienne Paubelle, Florence Zylbersztejn, Sawsaneh Alkhaeir, Felipe Suarez, Céline Callens, Michaël Dussiot, Françoise Isnard, Marie-Thérèse Rubio, Gandhi Damaj, Norbert-Claude Gorin, Jean-Pierre Marolleau, Renato C Monteiro, Ivan C Moura, Olivier Hermine
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/34139b8d626449939c5c19c402e95539
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:34139b8d626449939c5c19c402e95539
record_format	dspace
spelling	oai:doaj.org-article:34139b8d626449939c5c19c402e955392021-11-18T07:40:51ZDeferasirox and vitamin D improves overall survival in elderly patients with acute myeloid leukemia after demethylating agents failure.1932-620310.1371/journal.pone.0065998https://doaj.org/article/34139b8d626449939c5c19c402e955392013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23840388/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203The prognosis of acute myeloid leukemia (AML) in elderly (≥65 years) patients is poor and treatment remains non-consensual especially for those who are not eligible for intensive therapies. Our group has shown that in vitro the iron chelator deferasirox (DFX) synergizes with vitamin D (VD) to promote monocyte differentiation in primary AML cells. Herein, we present results from a retrospective case-control study in which the association of DFX (1-2 g/d) and 25-hydroxycholecalciferol (100,000 IU/week) (DFX/VD) was proposed to patients following demethylating agents failure. Median survival of patients treated with DFX/VD combination (n = 17) was significantly increased in comparison with matched patients receiving best supportive care (BSC) alone (n = 13) (10.4 versus 4 months respectively). In addition, the only factor associated to an increased overall survival in DFX/VD-treated patients was serum VD levels. We conclude that DFX/VD treatment correlated with increased overall survival of AML patients in this retrospective cohort of elderly patients.Etienne PaubelleFlorence ZylbersztejnSawsaneh AlkhaeirFelipe SuarezCéline CallensMichaël DussiotFrançoise IsnardMarie-Thérèse RubioGandhi DamajNorbert-Claude GorinJean-Pierre MarolleauRenato C MonteiroIvan C MouraOlivier HerminePublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 6, p e65998 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Etienne Paubelle Florence Zylbersztejn Sawsaneh Alkhaeir Felipe Suarez Céline Callens Michaël Dussiot Françoise Isnard Marie-Thérèse Rubio Gandhi Damaj Norbert-Claude Gorin Jean-Pierre Marolleau Renato C Monteiro Ivan C Moura Olivier Hermine Deferasirox and vitamin D improves overall survival in elderly patients with acute myeloid leukemia after demethylating agents failure.
description	The prognosis of acute myeloid leukemia (AML) in elderly (≥65 years) patients is poor and treatment remains non-consensual especially for those who are not eligible for intensive therapies. Our group has shown that in vitro the iron chelator deferasirox (DFX) synergizes with vitamin D (VD) to promote monocyte differentiation in primary AML cells. Herein, we present results from a retrospective case-control study in which the association of DFX (1-2 g/d) and 25-hydroxycholecalciferol (100,000 IU/week) (DFX/VD) was proposed to patients following demethylating agents failure. Median survival of patients treated with DFX/VD combination (n = 17) was significantly increased in comparison with matched patients receiving best supportive care (BSC) alone (n = 13) (10.4 versus 4 months respectively). In addition, the only factor associated to an increased overall survival in DFX/VD-treated patients was serum VD levels. We conclude that DFX/VD treatment correlated with increased overall survival of AML patients in this retrospective cohort of elderly patients.
format	article
author	Etienne Paubelle Florence Zylbersztejn Sawsaneh Alkhaeir Felipe Suarez Céline Callens Michaël Dussiot Françoise Isnard Marie-Thérèse Rubio Gandhi Damaj Norbert-Claude Gorin Jean-Pierre Marolleau Renato C Monteiro Ivan C Moura Olivier Hermine
author_facet	Etienne Paubelle Florence Zylbersztejn Sawsaneh Alkhaeir Felipe Suarez Céline Callens Michaël Dussiot Françoise Isnard Marie-Thérèse Rubio Gandhi Damaj Norbert-Claude Gorin Jean-Pierre Marolleau Renato C Monteiro Ivan C Moura Olivier Hermine
author_sort	Etienne Paubelle
title	Deferasirox and vitamin D improves overall survival in elderly patients with acute myeloid leukemia after demethylating agents failure.
title_short	Deferasirox and vitamin D improves overall survival in elderly patients with acute myeloid leukemia after demethylating agents failure.
title_full	Deferasirox and vitamin D improves overall survival in elderly patients with acute myeloid leukemia after demethylating agents failure.
title_fullStr	Deferasirox and vitamin D improves overall survival in elderly patients with acute myeloid leukemia after demethylating agents failure.
title_full_unstemmed	Deferasirox and vitamin D improves overall survival in elderly patients with acute myeloid leukemia after demethylating agents failure.
title_sort	deferasirox and vitamin d improves overall survival in elderly patients with acute myeloid leukemia after demethylating agents failure.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/34139b8d626449939c5c19c402e95539
work_keys_str_mv	AT etiennepaubelle deferasiroxandvitamindimprovesoverallsurvivalinelderlypatientswithacutemyeloidleukemiaafterdemethylatingagentsfailure AT florencezylbersztejn deferasiroxandvitamindimprovesoverallsurvivalinelderlypatientswithacutemyeloidleukemiaafterdemethylatingagentsfailure AT sawsanehalkhaeir deferasiroxandvitamindimprovesoverallsurvivalinelderlypatientswithacutemyeloidleukemiaafterdemethylatingagentsfailure AT felipesuarez deferasiroxandvitamindimprovesoverallsurvivalinelderlypatientswithacutemyeloidleukemiaafterdemethylatingagentsfailure AT celinecallens deferasiroxandvitamindimprovesoverallsurvivalinelderlypatientswithacutemyeloidleukemiaafterdemethylatingagentsfailure AT michaeldussiot deferasiroxandvitamindimprovesoverallsurvivalinelderlypatientswithacutemyeloidleukemiaafterdemethylatingagentsfailure AT francoiseisnard deferasiroxandvitamindimprovesoverallsurvivalinelderlypatientswithacutemyeloidleukemiaafterdemethylatingagentsfailure AT mariethereserubio deferasiroxandvitamindimprovesoverallsurvivalinelderlypatientswithacutemyeloidleukemiaafterdemethylatingagentsfailure AT gandhidamaj deferasiroxandvitamindimprovesoverallsurvivalinelderlypatientswithacutemyeloidleukemiaafterdemethylatingagentsfailure AT norbertclaudegorin deferasiroxandvitamindimprovesoverallsurvivalinelderlypatientswithacutemyeloidleukemiaafterdemethylatingagentsfailure AT jeanpierremarolleau deferasiroxandvitamindimprovesoverallsurvivalinelderlypatientswithacutemyeloidleukemiaafterdemethylatingagentsfailure AT renatocmonteiro deferasiroxandvitamindimprovesoverallsurvivalinelderlypatientswithacutemyeloidleukemiaafterdemethylatingagentsfailure AT ivancmoura deferasiroxandvitamindimprovesoverallsurvivalinelderlypatientswithacutemyeloidleukemiaafterdemethylatingagentsfailure AT olivierhermine deferasiroxandvitamindimprovesoverallsurvivalinelderlypatientswithacutemyeloidleukemiaafterdemethylatingagentsfailure
_version_	1718423089312694272

Deferasirox and vitamin D improves overall survival in elderly patients with acute myeloid leukemia after demethylating agents failure.

Ejemplares similares